Lifting the lid on GPCRs: The role of extracellular loops

British Journal of Pharmacology

Volumn 165, Issue 6, 2012, Pages 1688-1703

  Wheatley, M ^a   Wootten, D ^b   Conner, M T ^c   Simms, J ^b   Kendrick, R ^a   Logan, R T ^a   Poyner, D R ^c   Barwell, J ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

extracellular loop; family A GPCR; family B GPCR; G protein coupled receptor; ligand binding; receptor activation

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; AMYLIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCITONIN; CHEMOKINE RECEPTOR CXCR4; CORTICOTROPIN RELEASING FACTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; RHODOPSIN; SECRETIN;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DISULFIDE BOND; EXPERIMENTAL STUDY; EXTRACELLULAR SPACE; HUMAN; INTRACELLULAR SPACE; LIGAND BINDING; MEMBRANE BINDING; MEMBRANE STRUCTURE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RETINITIS PIGMENTOSA; REVIEW; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 84857483274     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01629.x     Document Type: Review

References (133)

1. Ahuja S, Hornak V, Yan ECY, Syrett N, Goncalves JA, Hirshfeld A, et al,. (2009). Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. Nat Struct Mol Biol 16: 168-175.
2. Assil-Kishawi I, Abou-Samra AB, (2002). Sauvagine cross-links to the second extracellular loop of the corticotropin-releasing factor type 1 receptor. J Biol Chem 277: 32558-32561.
3. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, Christopoulos A, (2007). Critical role for the second extracellular loop in the binding of both orthosteric and allosteric GPCR ligands. J Biol Chem 282: 25677-25686.
4. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al,. (2003). β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100: 11406-11411.
5. Baker JG, Hall IP, Hill SJ, (2003). Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signalling. Mol Pharmacol 64: 1357-1369.
6. Balaraman GS, Bhattacharya S, Nagarajan V, (2010). Structural insights into conformational stability of wild-type and mutant β1-adrenergic receptor. Biophys J 99: 568-577.
7. Ballesteros JA, Weinstein H, (1995). Integrated methods for the construction of 3-D models and computational probing of structure function relations in G-protein-coupled receptors. Methods Neurosci 25: 366-428.
8. BanÃ̈res J-L, Mesnier D, Martin A, Joubert L, Dumuis A, Bockaert J, (2005). Molecular characterization of a purified 5-HT4 receptor. J Biol Chem 280: 20253-20260.
9. Bichet DG, (2009). V2R mutations and nephrogenic diabetes insipidus. In:, Tao YX, (ed.). Progress in Molecular Biology and Translational Medicine. Academic Press: Burlington, MA, pp. 15-29.
10. Bokoch MP, Zou Y, Rasmussen SGF, Liu CW, Nygaard R, Rosenbaum DM, et al,. (2010). Ligand-specific regulation of the extracellular surface of a G-protein coupled receptor. Nature 463: 108-112.
11. Brelot A, Heveker N, Montes M, Alizon M, (2000). Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 275: 23736-23744.
12. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
13. Chien EY, Liu W, Zhao Q, Katrich V, Han GW, Hanson MA, et al,. (2010). Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330: 1091-1095.
14. Choe HW, Kim YJ, Park JH, Morizumi T, Pai EF, Krauss N, et al,. (2011). Crystal structure of metarhodopsin II. Nature 471: 651-655.
15. Chugunov AO, Simms J, Poyner DR, Dehouck Y, Rooman M, Gilis D, et al,. (2010). Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation. Mol Pharmacol 78: 394-401.
16. Conner M, Hawtin SR, Simms J, Wootten D, Lawson Z, Conner A, et al,. (2007). Systematic analysis of the entire second extracellular loop of the V1a vasopressin receptor: key residues, conserved throughout a G-protein-coupled receptor family, identified. J Biol Chem 282: 17405-17412.
17. Cook JV, Eidne KA, (1997). An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation. Endocrinology 138: 2800-2806.
18. Correa SA, Pignatari GC, Ferro ES, Pacheco NA, Costa-Neto CM, Pesquero JB, et al,. (2006). Role of the Cys18-Cys274 disulfide bond and of the third extracellular loop in the constitutive activation and internalization of angiotensin II type 1 receptor. Regul Pept 134: 132-140.
19. Davidson FF, Loewen PC, Khorana HG, (1994). Structure and function in rhodopsin. Proc Natl Acad Sci USA 91: 4029-4033.
20. Davidson JS, Flanagan CA, Davies PD, Hapgood J, Myburgh D, Elario R, et al,. (1996). Incorporation of an additional glycosylation site enhances expression of functional human gonadotropin-releasing hormone receptor. Endocrine 4: 207-212.
21. Déméné H, Grainer S, Muller D, Guillon G, Dufour MN, Delsuc MA, et al,. (2003). Active peptidic mimics of the second intracellular loop of the V(1A) vasopressin receptor are structurally related to the second intracellular rhodopsin loop: a combined 1H NMR and biochemical study. Biochemistry 42: 8204-8213.
22. Dong M, Pinon DI, Cox RF, Miller LJ, (2004). Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem 279: 31177-31182.
23. Dong M, Pinon DI, Asmann YW, Miller LJ, (2006). Possible endogenous agonist mechanism for the activation of secretin family G-protein-coupled receptors. Mol Pharmacol 70: 206-213.
24. Dong M, Lam PC, Pinon DI, Sexton PM, Abagyan R, Miller LJ, (2008). Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol 74: 413-422.
25. Dong M, Lam PC, Pinon DI, Orry A, Sexton PM, Abagyan R, et al,. (2010a). Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment. J Biol Chem 285: 9919-9931.
26. Dong M, Pinon DI, Bordner AJ, Miller LJ, (2010b). Elucidation of the active conformation of the amino terminus of receptor-bound secretin using intramolecular disulfide bond constraints. Bioorg Med Chem Lett 20: 6040-6044.
27. Dong M, Narang P, Pinon DI, Bordner AJ, Miller LJ, (2010c). Refinement of the pharmacophore of an agonist ligand of the secretin receptor using conformationally constrained cyclic hexapeptides. Peptides 31: 1094-1098.
28. Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM, et al,. (2011). Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem 286: 23888-23899.
29. Donnelly D, (1997). The arrangement of the transmembrane helices in the secretin receptor family of G-protein-coupled receptors. FEBS Lett 409: 431-436.
30. Duprez L, Parma J, van Sande J, Rodien P, Dumont JE, Vassart G, et al,. (1998). TSH receptor mutations and thyroid disease. Trends Endocrinol Metab 9: 133-140.
31. Elling CE, Raffetseder U, Nielsen SM, Schwartz TW, (2000). Disulfide bridge engineering in the tachykinin NK1 receptor. Biochemistry 39: 667-675.
32. Fillion D, Lemieux G, Basambombo LL, Lavigne P, Guillemette G, Leduc R, et al,. (2010). The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem 53: 2063-2075.
33. Fraser CM, (1989). Site-directed mutagenesis of β-adrenergic receptors: identification of conserved cysteine residues that independently affect ligand binding and receptor activation. J Biol Chem 264: 9266-9270.
34. Fredriksson R, Schiöth HB, (2005). The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 67: 1414-1425.
35. Frimurer TM, Bywater RP, (1999). Structure of the integral membrane domain of the GLP1 receptor. Proteins 35: 375-386.
36. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, et al,. (2009). A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1: 1ra1.
37. Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, et al,. (2009). Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Mol Pharmacol 75: 793-800.
38. Gnagey AL, Seidenberg M, Ellis J, (1999). Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol Pharmacol 56: 1245-1253.
39. Goin JC, Leiros CP, Borda E, Sterin-Borda L, (1997). Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 11: 77-83.
40. Goldfeld DA, Zhu K, Beuming T, Friesner RA, (2011). Successful prediction on the intra- and extracellular loops of four G-protein-coupled receptors. Proc Natl Acad Sci USA 108: 8275-8280.
41. Goncalvesa JA, South K, Ahujac S, Zaitsevad E, Opefi CA, Eilers M, et al,. (2010). Highly conserved tyrosine stabilizes the active state of rhodopsin. Proc Natl Acad Sci USA 107: 19861-19866.
42. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, et al,. (2008). A specific cholesterol binding site is established by the 2.8 Ã' structure of the human beta2-adrenergic receptor. Structure 16: 897-905.
43. 1a vasopressin receptor and assessment of their role in receptor signalling and expression. Biochem J 357: 73-81.
44. Hawtin SR, Simms J, Conner M, Lawson Z, Parslow RA, Trim J, et al,. (2006). Charged extracellular residues, conserved throughout a G-protein-coupled receptor family, are required for ligand binding, receptor activation and cell-surface expression. J Biol Chem 281: 38478-38488.
45. Hill SJ, (2006). G-protein-coupled receptors:past present & future. Br J Pharmacol 147 (Suppl. 1): S27-S37.
46. Hoare SR, (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10: 417-427.
47. Hofmann KP, Scheerer P, Hildebrand PW, Choe H-W, Park JH, Heck M, et al,. (2009). A G-protein-coupled receptor at work: the rhodopsin model. Trends Biochem Sci 34: 540-552.
48. Holst B, Schwartz TW, (2003). Molecular mechanisms of agonism and inverse agonism in melanocortin receptors. Ann NY Acad Sci 994: 1-11.
49. Holst B, Elling CE, Schwartz TW, (2000). Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. Mol Pharmacol 58: 263-270.
50. Houssami S, Findlay DM, Brady CL, Martin TJ, Epand RM, Moore EE, et al,. (1995). Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation. Mol Pharmacol 47: 798-809.
51. Howl J, Wheatley M, (1996). Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors. Biochem J 317: 577-582.
52. Howl J, Langel Ü, Hawtin SR, Valkna A, Yarwood NJ, Saar K, et al,. (1997). Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. FASEB J 11: 582-590.
53. Inooka H, Ohtaki T, Kitahara O, Ikegami T, Endo S, Kitada C, et al,. (2001). Conformation of a peptide ligand bound to its G-protein-coupled receptor. Nat Struct Biol 8: 161-165.
54. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al,. (2008). A 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
55. Janz JM, Fay JF, Farrens DL, (2003). Stability of dark state rhodopsin is mediated by a conserved ion pair in intradiscal loop E-2. J Biol Chem 278: 16982-16991.
56. Klco JM, Wiegand CB, Narzinski K, Baranski TJ, (2005). Essential role for the second extracellular loop in C5a receptor activation. Nat Struct Mol Biol 12: 320-326.
57. Kleinau G, Claus M, Jaeschke H, Mueller S, Neumann S, Paschke R, et al,. (2007). Contacts between ECL2 and TM6 determine basal activity of the thyroid-stimulating hormone receptor. J Biol Chem 282: 518-525.
58. Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, et al,. (1993). Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet 2: 813-814.
59. Laburthe M, Convineau A, Tan V, (2007). Class II G-protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28: 1631-1639.
60. Lagerström MC, Schiöth HB, (2008). Structural diversity of G-protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7: 339-357.
61. Lawson Z, Wheatley M, (2004). The third extracellular loop of G-protein-coupled receptors: more than just a linker between two important transmembrane helices. Biochem Soc Trans 32: 1048-1050.
62. 2A receptor structures reveal common features of GPCR activation. Nature 474: 521-525.
63. Lequin O, Bolbach G, Frank F, Convert O, Girault-Lagrange S, Chassaing G, et al,. (2002). Involvement of the second extracellular loop (E2) of the neurokinin-1 receptor in the binding of substance P. J Biol Chem 277: 22386-22394.
64. Li S, Liu X, Min L, Ascoli M, (2001). Mutations of the second extracellular loop of the human lutropin receptor emphasize the importance of receptor activation and de-emphasize the importance of receptor phosphorylation in agonist-induced internalization. J Biol Chem 276: 7968-7973.
65. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF, (2004). Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343: 1409-1438.
66. Luck MD, Carter PH, Gardella TJ, (1999). The (1-14) fragment of parathyroid hormone (PTH) activates intact and amino-terminally truncated PTH-1 receptors. Mol Endocrinol 13: 670-680.
67. Lüdeke S, Beck M, Yan EC, Sakmar TP, Siebert F, Vogel R, (2005). The role of Glu181 in the photoactivation of rhodopsin. J Mol Biol 353: 345-356.
68. 8]Substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. Br J Pharmacol 156: 36-47.
69. Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, et al,. (2008). Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights to mechanism of allosteric inhibition. J Mol Biol 381: 956-974.
70. Massotte D, Kieffer BL, (2005). The second extracellular loop: a damper for G-protein-coupled receptors? Nat Struct Mol Biol 12: 287-288.
71. May TL, Leach K, Sexton PM, Christopoulos A, (2007). Allosteric modulation of G-proetin-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
72. Michino M, Abola E,; GPCR Dock 2008 participants, Brooks CL 3rd, Dixon JS, Moult J, Stevens RC, (2009). Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8: 455-463.
73. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR, (2004). Gonadotropin-releasing hormone receptors. Endocr Rev 25: 235-275.
74. Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, et al,. (2011). Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem 286: 15895-15907.
75. Monaghan P, Thomas BE, Woznica I, Wittelsberger A, Mierke DF, Rosenblatt M, (2008). Mapping peptide hormone-receptor interactions using a disulfide-trapping approach. Biochemistry 47: 5889-5895.
76. 1-adrenergic receptor. Proc Nal Acad Sci USA 108: 8228-8232.
77. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR, (1996). Thrombin receptor activating mutations. J Biol Chem 271: 702-706.
78. Nawaratne V, Leach K, Felder CC, Sexton PM, Christopoulos A, (2010). Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor. J Biol Chem 285: 19012-19021.
79. Neumann JM, Couvineau A, Murail S, Lacapere JJ, Jamin N, Laburthe M, (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33: 314-319.
80. Nilsson IM, von Heijne G, (1993). Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. J Biol Chem 268: 5798-5801.
81. Noda K, Saad Y, Graham RM, Karnik SS, (1994). The high affinity state of the β2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. J Biol Chem 269: 6743-6752.
82. Ohyama K, Yamano Y, Sano T, Nakagomi Y, Hamakubo T, Morishima I, et al,. (1995). Disulfide bridges in extracellular domains of angiotensin II receptor type IA. Regul Pept 57: 141-147.
83. Oldham WM, Hamm HE, (2008). Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9: 60-71.
84. Ott TR, Troskie BE, Roeske RW, Illing N, Flanagan CA, Millar RP, (2002). Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist. Mol Endocrinol 10: 1079-1088.
85. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al,. (2000). Crystal structure of rhodopsin: a G-protein-coupled receptor. Science 289: 739-745.
86. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, et al,. (2006). Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 116: 760-768.
87. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP, (2008). Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454: 183-187.
88. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT, (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34: 303-310.
89. Peeters MC, van Westen GJ, Li Q, Ijzerman AP, (2011a). Importance of the extracellular loops in G-protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 32: 35-42.
90. Peeters MC, van Westen GJ, Guo D, Wisse LE, Muller CE, Beukers MW, et al,. (2011b). GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J 25: 632-643.
91. Pellegrini M, Bremer AA, Ulfers AL, Boyd ND, Mierke DF, (2001). Molecular characterization of the substance P*neurokinin-1 receptor complex: development of an experimentally based model. J Biol Chem 276: 22862-22867.
92. Piserchio A, Bisello A, Rosenblatt M, Chorev M, Mierke DF, (2000). Characterization of parathyroid hormone/receptor interactions: structure of the first extracellular loop. Biochemistry 39: 8153-8160.
93. Rakoczy EP, Kiel C, McKeone R, Stricher F, Serrano L, (2011). Analysis of disease-linked rhodopsin mutations based on structure, function, and protein stability calculations. J Mol Biol 405: 584-606.
94. Rana S, Baranski TJ, (2010). Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function. J Biol Chem 285: 31472-31483.
95. 2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
96. 2 adrenoceptor. Nature 469: 175-180.
97. 2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
98. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, et al,. (2011). Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 469: 236-240.
99. Rosenkilde MM, Benned-Jensen T, Frimurer TM, Schwartz TW, (2010). The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 31: 567-574.
100. Ruan K-H, So, S-P, Wu, J, Li D, Huang A, Kung J, (2001). Solution structure of the second extracellular loop of human thromboxane A2 receptor. Biochemistry 40: 275-280.
101. Runge S, Gram, C, Brauner-Osborne, H, Madsen, K, Knudsen, LB, Wulff, BS, (2003). Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem 278: 28005-28010.
102. Scarselli M, Li B, Kim S-K, Wess J, (2007). Multiple residues in ECL2 are critical for M3 receptor activation. J Biol Chem 282: 7385-7396.
103. Scheerer P, Park JH, Hildebrand W, Kim YJ, Krauss N, Choe HW, et al,. (2008). Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-502.
104. Schwartz TW, Holst B, (2007). Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 28: 359-446.
105. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE, (2006). Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46: 481-519.
106. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R, (2006). Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49: 534-553.
107. Shi L, Javitch JA, (2004). The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101: 440-445.
108. 1 receptor complex with doxepin. Nature 475: 65-70.
109. Soto CS, Fasnacht M, Zhu J, Forrest L, Honig B, (2008). Loop modeling: sampling, filtering, and scoring. Proteins 70: 834-843.
110. Standfuss J, Xie G, Edwards PC, Burghammer M, Oprian DD, Schertler GF, (2007). Crystal structure of a thermally stable rhodopsin mutant. J Mol Biol 372: 1179-1188.
111. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, et al,. (2011). The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471: 656-660.
112. Storjohann L, Holst B, Schwartz TW, (2008). A second disulfide bridge from the N-terminal domain to extracellular loop 2 dampens receptor activity in GPR39. Biochemistry 47: 9198-9207.
113. Sum CS, Tikhonova IG, Costanzi S, Gershengorn MC, (2009). Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem 284: 3529-3536.
114. Tarnow P, Schoneberg T, Krude H, Gruters A, Biebermann H, (2003). Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity. J Biol Chem 278: 48666-48673.
115. Thomas BE, Woznica I, Mierke DF, Wittelsberger A, Rosenblatt M, (2008). Conformational changes in the parathyroid hormone receptor associated with activation by agonist. Mol Endocrinol 22: 1154-1162.
116. Tian S, Choi WT, Liu D, Pesavento J, Wang Y, An J, et al,. (2005). Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J Virol 79: 12667-12673.
117. Tikhonova IG, Costanzi S, (2009). Unraveling the structure and function of G-protein-coupled receptors through NMR spectroscopy. Curr Pharm Des 15: 4003-4016.
118. Unal H, Jagannathan R, Bhat MB, Karnik SS, (2010). Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 285: 16341-16350.
119. Valant C, Sexton PM, Christopoulos A, (2009). Orthosteric/allosteric bitopic ligands. Mol Interv 9: 125-135.
120. Wacker D, Fenalti G, Brown MA, Katritch V, Abagyan R, Cherezov V, et al,. (2010). Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 132: 11443-11445.
121. Walker CS, Conner AC, Poyner DR, Hay DL, (2010). Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci 31: 476-483.
122. 1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
123. 1-adrenergic receptor. Nature 469: 241-245.
124. Wheatley M, Hawtin SR, (1999). Glycosylation of G-protein-coupled receptors for hormones central to normal reproductive functioning: its occurrence and role. Hum Reprod Update 5: 356-364.
125. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katrich V, et al,. (2010). Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
126. Xie G, Gross AK, Oprian DD, (2003). An opsin mutant with increased thermal stability. Biochemistry 42: 1995-2001.
127. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, et al,. (2011). Structure of an agonist-bound human A2A adenosine receptor. Science 332: 322-327.
128. Yang Y, Chen M, Kesterson RA, Harmon CM, (2007). Structural insights into the role of the ACTH receptor cysteine residues on receptor function. Am J Physiol 293: R1120-R1126.
129. Zeng FY, Soldner A, Schöneberg T, Wess J, (1999). Conserved extracellular cysteine pair in the M3 muscarinic acetylcholine receptor is essential for proper cell surface localization but not G-protein coupling. J Neurochem 72: 2404-2414.
130. Zhang L, DeHaven RN, Goodman M, (2002). NMR and modeling studies of a synthetic extracellular loop II of the ΰ-opioid receptor in a DPC micelle. Biochemistry 41: 61-68.
131. Zhao MM, Hwa J, Perez DM, (1996). Identification of critical extracellular loop residues involved in α1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol 50: 1118-1126.
132. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, et al,. (2008). Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 14: 855-862.
133. Zhou H, Tai HH, (2000). Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding. Arch Biochem Biophys 373: 211-217.